Last reviewed · How we verify
Methadone plus Ketamine
At a glance
| Generic name | Methadone plus Ketamine |
|---|---|
| Also known as | methadone and S(+)-ketamine, Cristália®, São Paulo, Brazil |
| Sponsor | Universidade Federal de Santa Maria |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Ketamine for Opioid Use Disorder (PHASE2)
- The MDK Study: Using a Combination of Methadone-dexmedetomidine-ketamine for Postoperative Pain Control in Patients Undergoing Complex Spine Surgeries. (PHASE4)
- Reducing Pain With Methadone and Ketamine in Liver Transplant (PHASE4)
- Outcome of Multimodal Anesthesia Bern (NA)
- Perioperative Opioid-induced Hyperalgesia and Its Prevention With Ketamine and Methadone (NA)
- A Study to Evaluate the Efficacy and Safety of REL-1017 As Adjunctive Treatment of Major Depressive Disorder (MDD) (PHASE3)
- Ketamine for OUD and Comorbid Depression (OUDCD) (PHASE1)
- Effects of Hallucinogens and Other Drugs on Mood and Performance (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Methadone plus Ketamine CI brief — competitive landscape report
- Methadone plus Ketamine updates RSS · CI watch RSS
- Universidade Federal de Santa Maria portfolio CI